Peptides derived from human insulin-like growth factor-II mRNA binding protein 3 can induce human leukocyte antigen-A2-restricted cytotoxic T lymphocytes reactive to cancer cells

Cancer Science

Volumn 102, Issue 1, 2011, Pages 71-78

  Tomita, Yusuke ^a   Harao, Michiko ^a   Senju, Satoru ^a   Imai, Katsunori ^a   Hirata, Shinya ^a   Irie, Atsushi ^a   Inoue, Mitsuhiro ^a   Hayashida, Yuki ^a   Yoshimoto, Kentaro ^a   Shiraishi, Kenji ^a   Mori, Takeshi ^a   Nomori, Hiroaki ^a   Kohrogi, Hirotsugu ^a   Nishimura, Yasuharu ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HUMAN IMMUNODEFICIENCY VIRUS PEPTIDE; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; INSULIN LIKE GROWTH FACTOR 2 MRNA BINDING PROTEIN 3; INSULIN LIKE GROWTH FACTOR 2 MRNA BINDING PROTEIN 3 A2 1 PEPTIDE; INSULIN LIKE GROWTH FACTOR 2 MRNA BINDING PROTEIN 3 A2 10 PEPTIDE; INSULIN LIKE GROWTH FACTOR 2 MRNA BINDING PROTEIN 3 A2 11 PEPTIDE; INSULIN LIKE GROWTH FACTOR 2 MRNA BINDING PROTEIN 3 A2 12 PEPTIDE; INSULIN LIKE GROWTH FACTOR 2 MRNA BINDING PROTEIN 3 A2 13 PEPTIDE; INSULIN LIKE GROWTH FACTOR 2 MRNA BINDING PROTEIN 3 A2 14 PEPTIDE; INSULIN LIKE GROWTH FACTOR 2 MRNA BINDING PROTEIN 3 A2 15 PEPTIDE; INSULIN LIKE GROWTH FACTOR 2 MRNA BINDING PROTEIN 3 A2 16 PEPTIDE; INSULIN LIKE GROWTH FACTOR 2 MRNA BINDING PROTEIN 3 A2 17 PEPTIDE; INSULIN LIKE GROWTH FACTOR 2 MRNA BINDING PROTEIN 3 A2 18 PEPTIDE; INSULIN LIKE GROWTH FACTOR 2 MRNA BINDING PROTEIN 3 A2 19 PEPTIDE; INSULIN LIKE GROWTH FACTOR 2 MRNA BINDING PROTEIN 3 A2 2 PEPTIDE; INSULIN LIKE GROWTH FACTOR 2 MRNA BINDING PROTEIN 3 A2 20 PEPTIDE; INSULIN LIKE GROWTH FACTOR 2 MRNA BINDING PROTEIN 3 A2 3 PEPTIDE; INSULIN LIKE GROWTH FACTOR 2 MRNA BINDING PROTEIN 3 A2 4 PEPTIDE; INSULIN LIKE GROWTH FACTOR 2 MRNA BINDING PROTEIN 3 A2 5 PEPTIDE; INSULIN LIKE GROWTH FACTOR 2 MRNA BINDING PROTEIN 3 A2 6 PEPTIDE; INSULIN LIKE GROWTH FACTOR 2 MRNA BINDING PROTEIN 3 A2 7 PEPTIDE; INSULIN LIKE GROWTH FACTOR 2 MRNA BINDING PROTEIN 3 A2 8 PEPTIDE; INSULIN LIKE GROWTH FACTOR 2 MRNA BINDING PROTEIN 3 A2 9 PEPTIDE; MONOCLONAL ANTIBODY; PEPTIDE DERIVATIVE; SOMATOMEDIN BINDING PROTEIN 3; UNCLASSIFIED DRUG;

ADRENAL GLAND; ANIMAL MODEL; ARTICLE; BILE DUCT CARCINOMA; BLADDER CANCER; BONE MARROW; BRAIN; BREAST CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER TISSUE; CELL KILLING; CHRONIC MYELOID LEUKEMIA; COLON; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG TARGETING; ESOPHAGUS CANCER; FETUS (ANATOMY); FETUS LIVER; FETUS LUNG; HEART; HUMAN; HUMAN CELL; IMMUNOGENICITY; KIDNEY; LIVER; LUNG; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPH NODE; LYMPHOMA; MAMMARY GLAND; MOUSE; NONHUMAN; OSTEOSARCOMA; OVARY; PANCREAS; PERIPHERAL BLOOD MONONUCLEAR CELL; PLACENTA; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; SALIVARY GLAND; SKELETAL MUSCLE; SMALL INTESTINE; SOFT TISSUE TUMOR; SPINAL CORD; SPLEEN; STOMACH; STOMACH CANCER; TESTIS; THYMUS; THYROID GLAND; TRACHEA; UTERINE CERVIX CANCER; UTERUS;

ANIMALS; CELL LINE, TUMOR; EPITOPES, T-LYMPHOCYTE; HLA-A2 ANTIGEN; HUMANS; LUNG NEOPLASMS; MICE; NEOPLASMS; PEPTIDE FRAGMENTS; RNA-BINDING PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 78650219028     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01780.x     Document Type: Article

References (41)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Bunn PA Jr., Thatcher N. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction. Oncologist 2008; 13(Suppl 1): 1-4.
3. Ruttinger D, Hatz RA, Jauch KW, Fox BA. Current immunotherapeutic strategies in lung cancer. Surg Oncol Clin N Am 2007; 16: 901-18, x.
4. Hirschowitz EA, Yannelli JR. Immunotherapy for lung cancer. Proc Am Thorac Soc 2009; 6: 224-32.
5. Romero P. Current state of vaccine therapies in non-small-cell lung cancer. Clin Lung Cancer 2008; 9 (Suppl 1): S28-36.
6. Findeis-Hosey JJ, Yang Q, Spaulding BO, Wang HL, Xu H. IMP3 expression is correlated with histologic grade of lung adenocarcinoma. Hum Pathol 2010; 41: 477-84.
7. Jiang Z, Chu PG, Woda BA et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 2006; 7: 556-64.
8. Mueller-Pillasch F, Lacher U, Wallrapp C et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 1997; 14: 2729-33.
9. Zheng W, Yi X, Fadare O et al. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol 2008; 32: 304-15.
10. Liao B, Hu Y, Herrick DJ, Brewer G. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem 2005; 280: 18517-24.
11. Vikesaa J, Hansen TV, Jonson L et al. RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J 2006; 25: 1456-68.
12. Schaeffer DF, Owen DR, Lim HJ et al. Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival. BMC Cancer 2010; 10: 59.
13. Sitnikova L, Mendese G, Liu Q et al. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res 2008; 14: 1701-6.
14. Wang T, Fan L, Watanabe Y et al. L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. Br J Cancer 2003; 88: 887-94.
15. Suda T, Tsunoda T, Daigo Y, Nakamura Y, Tahara H. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci 2007; 98: 1803-8.
16. Kono K, Mizukami Y, Daigo Y et al. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci 2009; 100: 1502-9.
17. Mizukami Y, Kono K, Daigo Y et al. Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma. Cancer Sci 2008; 99: 1448-54.
18. Browning M, Krausa P. Genetic diversity of HLA-A2: evolutionary and functional significance. Immunol Today 1996; 17: 165-70.
19. Nakamura T, Furukawa Y, Nakagawa H et al. Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection. Oncogene 2004; 23: 2385-400.
20. Taniwaki M, Daigo Y, Ishikawa N et al. Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer. Int J Oncol 2006; 29: 567-75.
21. Saito-Hisaminato A, Katagiri T, Kakiuchi S, Nakamura T, Tsunoda T, Nakamura Y. Genome-wide profiling of gene expression in 29 normal human tissues with a cDNA microarray. DNA Res 2002; 9: 35-45.
22. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 1997; 185: 2043-51.
23. Firat H, Garcia-Pons F, Tourdot S et al. H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. Eur J Immunol 1999; 29: 3112-21.
24. Nakatsura T, Senju S, Yamada K, Jotsuka T, Ogawa M, Nishimura Y. Gene cloning of immunogenic antigens overexpressed in pancreatic cancer. Biochem Biophys Res Commun 2001; 281: 936-44.
25. Imai K, Hirata S, Irie A et al. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers. Clin Cancer Res 2008; 14: 6487-95.
26. Tahara-Hanaoka S, Sudo K, Ema H, Miyoshi H, Nakauchi H. Lentiviral vector-mediated transduction of murine CD34(-) hematopoietic stem cells. Exp Hematol 2002; 30: 11-17.
27. Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM. Development of a self-inactivating lentivirus vector. J Virol 1998; 72: 8150-7.
28. Harao M, Hirata S, Irie A et al. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL. Int J Cancer 2008; 123: 2616-25.
29. Komori H, Nakatsura T, Senju S et al. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 2006; 12: 2689-97.
30. Naito K, Ueda Y, Itoh T et al. Mature dendritic cells generated from patient-derived peripheral blood monocytes in one-step culture using streptococcal preparation OK-432 exert an enhanced antigen-presenting capacity. Int J Oncol 2006; 28: 1481-9.
31. Inoue M, Senju S, Hirata S et al. Identification of SPARC as a candidate target antigen for immunotherapy of various cancers. Int J Cancer 2010; 127: 1393-403.
32. Rubio V, Stuge TB, Singh N et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 2003; 9: 1377-82.
33. Betts MR, Brenchley JM, Price DA et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281: 65-78.
34. Bourgault Villada I, Moyal Barracco M, Ziol M et al. Spontaneous regression of grade 3 vulvar intraepithelial neoplasia associated with human papillomavirus-16-specific CD4(+) and CD8(+) T-cell responses. Cancer Res 2004; 64: 8761-6.
35. Yokomine K, Senju S, Nakatsura T et al. The forkhead box M1 transcription factor as a candidate of target for anti-cancer immunotherapy. Int J Cancer 2010; 126: 2153-63.
36. Monji M, Nakatsura T, Senju S et al. Identification of a novel human cancer/testis antigen, KM-HN-1, recognized by cellular and humoral immune responses. Clin Cancer Res 2004; 10: 6047-57.
37. Makita M, Hiraki A, Azuma T et al. Antilung cancer effect of WT1-specific cytotoxic T lymphocytes. Clin Cancer Res 2002; 8: 2626-31.
38. Kikuchi T, Daigo Y, Katagiri T et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 2003; 22: 2192-205.
39. Kobel M, Xu H, Bourne PA et al. IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Mod Pathol 2009; 22: 469-75.
40. Munz C, Lunemann JD, Getts MT, Miller SD. Antiviral immune responses: triggers of or triggered by autoimmunity? Nat Rev Immunol 2009; 9: 246-58.
41. Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203-13.